| Case Name | Date Filed | Judge | Drug | Patent No(s). |
| Novartis Pharma. Corp. v. Alvogen Pine Brook, Inc., 13-0052 (D. Del.) | Jan. 4, 2013 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023; 6,335,031 |
| AstraZeneca AB v. Dr. Reddy’s Labs., Inc., 13-0091 (D.N.J.) | Jan. 4, 2013 | Hon. Joel A. Pisano | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 6,926,907; 5,714,504; 7,745,466; 7,411,070; 6,369,085 |
| Allergan, Inc. v. Apotex Inc., 13-0016 (M.D.N.C.) | Jan. 8, 2013 | Hon. Catherine C. Eagles | Latisse® (bimatoprost topical solution, 0.03%) | 8,263,054 |
| Cadence Pharma., Inc. v. Fresenius Kabi USA, LLC, 13-0139 (S.D. Ca.) | Jan. 17, 2013 | Hon. Dana M. Sabraw | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Horizon Pharma, Inc. v. Par Pharma. Cos., Inc., 13-0102 (D. Del.) | Jan. 17, 2013 | Hon. Leonard P. Stark | Duexis® (famotidine / ibuprofen tablets) | 8,309,127; 8,318,202 |
| Cadence Pharma., Inc. v. Fresenius Kabi USA, LLC, 13-0453 (N.D. Ill.) | Jan. 18, 2013 | Hon. Gary Feinerman | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Jazz Pharma., Inc. v. Amneal Pharma., LLC, 13-0391 (N.J.D) | Jan. 18, 2013 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 6,472,431; 6,780,889; 7,262,219; 7,851,506; 7,895,059; 8,263,650; 8,324,275 |
| Endo Pharma. Inc. v. Impax Labs., Inc., 13-0435 (S.D.N.Y.) | Jan. 18, 2013 | Hon. Thomas P. Griesa | Opana® ER (oxymorphone hydrochloride extended-release tablets) | 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,309,060; 8,329,216 |
| Endo Pharma. Inc. v. Actavis, Inc., 13-0436 (S.D.N.Y.) | Jan. 18, 2013 | Hon. Thomas P. Griesa | Opana® ER (oxymorphone hydrochloride extended-release tablets) | 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,309,060; 8,329,216 |
| Hoffman-La Roche Inc. v. Aurobindo Pharma Ltd., 13-0124 (D. Del.) | Jan. 22, 2013 | Hon Leonard P. Stark | Boniva® Once-Monthly (ibandronate sodium tablets) | 7,718,634; 7,410,957; 6,294,196 |
| Glenmark Generics Ltd. v. GlaxoSmithKline, PLC, 13-0135 (D. Del.) | Jan. 24, 2013 | Hon. Christopher J. Burke | Bactroban® (mupirocin calcium cream) | 6,025,389; 5,569,672 |
| AbbVie, Inc. v. Sun Pharma. Indus. Ltd., 13-0138 (D. Del.) | Jan. 24, 2013 | Hon. Gregory M. Sleet | Zemplar® (paricalcitol capsules) | 5,597,815 |
| Pfizer Inc. v. Wockhardt Ltd., 13-0143 (D. Del.) | Jan. 25, 2013 | Hon. Gregory M. Sleet | Lyrica® (pregabalin oral solution) | 6,197,819 |
| Santarus, Inc. v. Mylan Inc., 13-0145 (D. Del.) | Jan. 28, 2013 | Hon. Richard G. Andrews | Fenoglide® (fenofibrate orally disintegrating tablets) | 7,658,944; 8,124,125 |
| Auxilium Pharma., Inc. v. Upsher-Smith Labs., Inc., 13-0148 (D. Del.) | Jan. 28, 2013 | Hon. Sue L. Robinson | Testim® (testosterone transdermal gel) | 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; 8,063,029; 8,178,518 |
| Depomed, Inc. v. Purdue Pharma L.P., 13-0571 (D.N.J.) | Jan. 29, 2013 | Hon. Joel A. Pisano | OcyContin® (oxycodone hydrochloride controlled-release tablets) | 6,340,475; 6,635,280; 6,723,340 |
| Santarus, Inc. v. Mylan Pharma., Inc., 13-0017 (N.D.W.V.) | Jan. 30, 2013 | Hon. Irene M. Keeley | Fenoglide® (fenofibrate orally disintegrating tablets) | 7,658,944; 8,124,125 |
| Purdue Pharma L.P. v. Epic Pharma, LLC, 13-0683 (S.D.N.Y.) | Jan. 30, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 7,674,799; 7,674,800; 7,683,072 |
| Purdue Pharma L.P. v. Impax Labs., Inc., 13-0684 (S.D.N.Y.) | Jan. 30, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 7,674,799; 7,674,800; 7,683,072 |
| Merck Sharp & Dohme Corp. v. APP Pharma., Inc., 13-0166 (D. Del.) | Jan. 31, 2013 | Hon. Richard G. Andrews | Integrilin® (eptifibatide injection) | 5,807,825; 5,747,447; 5,968,902 |
| Purdue Pharma L.P. v. Watson Labs., Inc.—Florida, 13-0762 (S.D.N.Y.) | Feb. 1, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 8,309,060 |
| Purdue Pharma L.P. v. Impax Labs., Inc., 13-0763 (S.D.N.Y.) | Feb. 1, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 8,114,383; 8,309,060 |
| Cadence Pharma., Inc. v. Sandoz Inc., 13-0278 (S.D. Ca.) | Feb. 4, 2013 | Hon. John A. Houston | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Cadence Pharma., Inc. v. Sandoz Inc., 13-0733 (D.N.J.) | Feb. 5, 2013 | Hon. Freda L. Wolfson | Ofirmev® (acetaminophen for injection) | 6,028,222; 6,992,218 |
| Sucampo AG v. Anchen Pharma., Inc., 13-0202 (D. Del.) | Feb. 7, 2013 | Hon. Gregory M. Sleet | Amitiza® (lubiprostone capsules) | 6,414,016; 7,795,312; 8,026,393; 8,071,613; 8,097,653; 8,338,639 |
| Unimed Pharma., LLC v. Perrigo Co., 13-0236 (D. Del.) | Feb. 15, 2013 | Hon. Leonard P. Stark | AndroGel® (testosterone gel) | 6,503,894 |
| Novartis Pharma. Corp. v. Actavis LLC, 13-1028 (D.N.J.) | Feb. 20, 2013 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid for injection); Reclast® (zoledronic acid for injection) | 7,932,241; 8,052,987; 8,324,189 |
| Purdue Pharma L.P. v. Watson Labs., Inc.—Florida, 13-1272 (S.D.N.Y.) | Feb. 25, 2013 | Hon. Sidney H. Stein | OcyContin® (oxycodone hydrochloride extended-release tablets) | 8,337,888 |
| Depomed, Inc. v. Watson Labs., Inc.—Florida, 13-0342 (D. Del.) | Feb. 28, 2013 | Hon. Sue L. Robinson | Glumetza® (metformin hydrochloride extended-release tablets) | 6,488,962; 6,723,340; 6,635,280; 6,340,475 |
| Eli Lilly and Co. v. Accord Healthcare, Inc., USA, 13-0335 (S.D. Ind.) | Feb. 28, 2013 | Hon. William T. Lawrence | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
| Endo Pharma. Inc. v. Watson Pharma., Inc., 13-0192 (E.D. Tex.) | Feb. 28, 2013 | Hon. J. Rodney Gilstrap | Fortesta® (testosterone gel) | 6,319,913; 6,579,865 |
| AbbVie Inc. v. The Kennedy Trust for Rheumatology Research, 13-1358 (S.D.N.Y.) | Feb. 28, 2013 | Hon. Paul A. Crotty | Humira® (adalimumab) | 8,298,537; 8,383,120 |
| G.D. Searle LLC v. Lupin Pharma., Inc., 13-0121 (E.D. Va.) | Mar. 5, 2013 | Hon. Arenda L. Wright Allen | Celebrex® (celecoxib capsules) | RE44,048 |
| Novartis Pharma. Corp. v. Alvogen Pine Brook, Inc., 13-0370 (D. Del.) | Mar. 7, 2013 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023; 6,335,031 |
| Novartis Pharma. Corp. v. Actavis, Inc., 13-0371 (D. Del.) | Mar. 7, 2013 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended-release film) | 6,316,023; 6,335,031 |
| Merck, Sharp & Dohme Corp. v. Hetero USA Inc., 13-1402 (D.N.J.) | Mar. 7, 2013 | Hon. Jerome B. Simandle | Sustiva® (efavirenz tablets) | 6,639,071; 6,939,964; 6,673,372 |
| Janssen Products, L.P. v. Hetero Drugs, Ltd., 13-1444 (D.N.J.) | Mar. 8, 2013 | Hon. William H. Walls | Prezista® (darunavir) | 7,126,015; 7,595,408 |
| Intendis Gmbh v. Glenmark Generics Ltd., 13-0421 (D. Del.) | Mar. 14, 2013 | Hon. Sue L. Robinson | Finacea® (azelaic acid gel) | 6,534,070 |
| Apotex, Inc. v. Teva Pharma. Indus., Ltd., 13-60601 (S.D. Fl.) | Mar. 14, 2013 | Hon. Donald M. Middlebrooks | Accupril® (quinapril hydrochloride) | 6,531,486 |
| Boehringer Ingelheim Pharma Gmbh & Co. KG v. Kremers Urban Pharma. Inc., 13-1580 (D.N.J.) | Mar. 14, 2013 | Hon. Noel L. Hillman | Aggrenox® (dipyridamole / aspirin extended-release capsules) | 6,015,577 |
| Pharmacia & Upjohn Co. LLC v. Apotex Inc., 13-2034 (N.D. Ill.) | Mar. 15, 2013 | Hon. Matthew F. Kennelly | Zyvox® (linezolid tablets) | 5,688,792 |
| AstraZeneca AB v. Watson Labs., Inc.—Florida, 13-1669 (D.N.J.) | Mar. 19, 2013 | Hon. Joel A. Pisano | Nexium® (esomeprazole magnesium delayed-release capsules) | 5,714,504; 5,877,192; 6,369,085; 6,875,872; 7,411,070 |
| Pfizer Inc. v. Lupin Ltd., 13-1778 (D.N.J.) | Mar. 21, 2013 | Hon. Dennis M. Cavanaugh | Detrol® LA (tolterodine tartrate extended-release capsules) | 6,630,162; 6,770,295 |
| Millenium Pharma., Inc. v. Fresenius KABI USA, LLC, 13-0467 (D. Del.) | Mar. 22, 2013 | Hon. Gregory M. Sleet | Velcade® (bortezomib) | 6,713,446; 6,958,319 |
| Takeda Pharma. U.S.A., Inc. v. Amneal Pharma., LLC, 13-0493 (D. Del.) | Mar. 28, 2013 | Hon. Sue L. Robinson | Colcrys® (colchicine) | 7,619,004; 7,601,758; 7,820,681; 7,915,269; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,097,655 |
| Mallinckrodt LLC v. Taro Pharma. Indus. Ltd., 13-0494 (D. Del.) | Mar. 28, 2013 | Hon. Richard G. Andrews | Pennsaid® (diclofenac sodium topical solution) | 8,217,078 |
| Unimed Pharma., LLC v. Watson Labs., Inc., 13-0496 (D. Del.) | Mar. 29, 2013 | Hon. Leonard P. Stark | AndroGel® (testosterone gel) | 6,503,894 |
